시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 간시클로비르 시장 보고서(2025년)
Ganciclovir Global Market Report 2025
상품코드 : 1764324
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,272,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,065,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,859,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

간시클로비르 시장 규모는 향후 수년간 급성장이 예상됩니다. 시장 성장은 현장에서의 헬스케어 인프라의 확대 등에 기인하고 있습니다. 예측 기간 중에 예상되는 주요 동향으로는 약물전달법의 혁신, 서방형제제의 창출, 병용 요법의 진보, CMV 조기 발견을 위한 고도 진단 툴의 사용, CMV 감염증의 맞춤형 치료 전략 출현 등을 들 수 있습니다.

사이토메갈로바이러스(CMV) 감염증의 이환율 증가는 향후 몇 년간 간시클로비르 시장의 성장을 가속할 것으로 예측됩니다. CMV 감염자 증가는 주로 면역 결핍자 증가에 기인하며 면역 방어 기능이 저하되어 바이러스의 재활성화 및 감염에 대한 취약성이 높아지고 있습니다. 예를 들어, 2025년 1월, 미국 공중보건기구인 질병대책예방센터(CDC)는 미국 소아의 3명 중 1명이 5세까지 CMV에 감염되고 성인의 절반 이상이 40세까지 감염된다고 보고했습니다. 치료기관인 미국 국립의학도서관은 매년 약 4만명의 유아가 선천성 CMV(cCMV)에 감염되어 태어나며, 그 중 약 400명(1%)이 감염으로 사망하고 약 8,000명(25%)이 장기 합병증으로 고통받고 있다고 보고했습니다.

헬스케어 지출 증가는 간시클로비르 시장의 향후 성장을 견인할 것으로 예측됩니다. 하지만 의료 기기와 교육이 필요하고, 고액의 진단 및 치료 절차에 대한 의존도가 높아지는 과제 또한 존재합니다. 영국 통계청은 2024년 동국의 헬스케어 지출이 약 4,213억 2,000만 달러(3,170억 파운드)에 달하였으며 2023년보다 6.5% 증가했다고 보고했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 팬데믹과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Ganciclovir is a man-made antiviral drug used to treat cytomegalovirus (CMV) infections, especially in individuals with weakened immune systems, such as those with HIV/AIDS or organ transplant recipients. As a nucleoside analogue, it works by blocking viral DNA synthesis, thereby stopping the replication of CMV. This aids in controlling the viral load and lowers the risk of disease progression.

Ganciclovir is primarily available in two forms: injection and oral. The injectable version is administered intravenously and is mainly used to treat or prevent CMV infections in immunocompromised patients. It comes in different dosage forms, including tablets, intravenous solutions, and eye gels. These products are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used in multiple applications, including CMV retinitis, prevention of CMV infections in organ transplant recipients, and other related conditions.

The ganciclovir market research report is one of a series of new reports from The Business Research Company that provides ganciclovir market statistics, including the ganciclovir industry global market size, regional shares, competitors with the ganciclovir market share, detailed ganciclovir market segments, market trends, and opportunities, and any further data you may need to thrive in the ganciclovir industry. This ganciclovir market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ganciclovir market size has grown rapidly in recent years. It will grow from $1.22 billion in 2024 to $1.37 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth during the historic period can be credited to the rising demand for antiviral therapies, increased adoption of targeted treatments, a growing requirement for effective solutions in transplant patients, heightened attention on chronic viral infections, and improved access to healthcare in developing areas.

The ganciclovir market size is expected to see rapid growth in the next few years. It will grow to $2.20 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be credited to the increased adoption of antiviral therapies, a rising prevalence of immunocompromised conditions, greater awareness of CMV infections, progress in diagnostic technologies, and the expansion of healthcare infrastructure in emerging markets. Key trends expected during the forecast period include innovations in drug delivery methods, the creation of extended-release formulations, advancements in combination therapies, the use of advanced diagnostic tools for early detection of CMV, and the emergence of personalized treatment strategies for CMV infections.

The increasing incidence of cytomegalovirus (CMV) infections is anticipated to drive the growth of the ganciclovir market in the coming years. CMV infections, caused by a common herpesvirus, can remain latent and reactivate in individuals with weakened immune systems, leading to severe complications such as retinitis, pneumonia, and gastrointestinal disorders-particularly among transplant recipients and individuals with HIV/AIDS. The rise in CMV cases is largely due to the growing population of immunocompromised individuals, whose weakened immune defenses heighten vulnerability to viral reactivation and transmission. Ganciclovir plays a vital role in providing effective antiviral treatment, underlining its importance in managing the increasing CMV infection rates among at-risk populations. For example, in January 2025, the Centers for Disease Control and Prevention (CDC), a U.S.-based public health agency, reported that 1 in 3 children in the U.S. contracts CMV by age 5, and over half of adults are infected by age 40. Furthermore, in October 2022, the National Library of Medicine, a U.S.-based medical institution, noted that approximately 40,000 infants are born each year with congenital CMV (cCMV); of these, around 400 (1%) die from the infection, and nearly 8,000 (25%) suffer long-term complications. Thus, the rising occurrence of CMV infections is contributing to the expansion of the ganciclovir market.

The increase in healthcare expenditure is expected to drive the growth of the ganciclovir market in the future. Healthcare expenditure refers to the total spending on medical services, treatments, and public health by individuals, insurance providers, and governments. This rise in spending is largely attributed to advancements in medical technologies, which often come with high development and implementation costs, necessitate specialized equipment and training, and lead to increased reliance on costly diagnostic and therapeutic procedures. Higher healthcare expenditure facilitates the use of ganciclovir by expanding access to antiviral treatments for managing cytomegalovirus (CMV) infections, particularly among immunocompromised individuals. For example, in May 2024, the Office for National Statistics, a government agency in the UK, reported that the country's healthcare spending in 2024 reached about $421.32 billion (£317 billion), marking a 6.5% rise from 2023. Thus, the growing healthcare expenditure is contributing to the expansion of the ganciclovir market.

In May 2022, Cheplapharm Arzneimittel GmbH, a pharmaceutical company based in Germany, acquired the rights to Valcyte from Roche Holdings AG for an undisclosed sum. This acquisition expands Cheplapharm's antiviral portfolio, reinforces its position in CMV treatment, and supports its strategy of increasing global access to essential, guideline-recommended medications. Roche Holdings AG, headquartered in Switzerland, is a pharmaceutical company that provides therapies for cytomegalovirus (CMV) infections, including ganciclovir.

Major players in the ganciclovir market are Roche Holding AG, Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Dr. Reddy's Laboratories Ltd., Cipla Ltd., Fareva Group, Zydus Lifesciences Ltd., Natco Pharma Ltd., Ajanta Pharma Ltd., Micro Labs Ltd., Taj Pharmaceuticals Ltd., Sunways Pvt. Ltd., Accord Healthcare Ltd., AdvaCare Pharma USA, Trifarma S.p.A., Actiza Pharmaceutical Pvt. Ltd., Bakul Group of Companies, Doctor Wonder Healthcare Pvt. Ltd., Sujalam Chemicals, and Aetos Pharma Pvt. Ltd.

North America was the largest region in the ganciclovir market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ganciclovir report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ganciclovir market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ganciclovir market consists of sales of ganciclovir injectable solutions, ganciclovir capsules, ganciclovir oral solutions, and ganciclovir ophthalmic gels. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ganciclovir Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ganciclovir market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for ganciclovir ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ganciclovir market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Ganciclovir Market Characteristics

3. Ganciclovir Market Trends And Strategies

4. Ganciclovir Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Ganciclovir Growth Analysis And Strategic Analysis Framework

6. Ganciclovir Market Segmentation

7. Ganciclovir Market Regional And Country Analysis

8. Asia-Pacific Ganciclovir Market

9. China Ganciclovir Market

10. India Ganciclovir Market

11. Japan Ganciclovir Market

12. Australia Ganciclovir Market

13. Indonesia Ganciclovir Market

14. South Korea Ganciclovir Market

15. Western Europe Ganciclovir Market

16. UK Ganciclovir Market

17. Germany Ganciclovir Market

18. France Ganciclovir Market

19. Italy Ganciclovir Market

20. Spain Ganciclovir Market

21. Eastern Europe Ganciclovir Market

22. Russia Ganciclovir Market

23. North America Ganciclovir Market

24. USA Ganciclovir Market

25. Canada Ganciclovir Market

26. South America Ganciclovir Market

27. Brazil Ganciclovir Market

28. Middle East Ganciclovir Market

29. Africa Ganciclovir Market

30. Ganciclovir Market Competitive Landscape And Company Profiles

31. Ganciclovir Market Other Major And Innovative Companies

32. Global Ganciclovir Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ganciclovir Market

34. Recent Developments In The Ganciclovir Market

35. Ganciclovir Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기